Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Global Pediatrics Partnering 2010-2021: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
Global Pediatrics Partnering 2010 to 2021 provides the full collection of Pediatrics…
Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease will be highlighted in an oral presentation
Topline data from the Phase 2 HERACLES clinical trial with Maa…
GARCHING, Germany–(BUSINESS WIRE)–ITM AG today announced that the company will present a poster describing the clinical trial design for its ongoing phase III trial COMPETE for their lead candidate, no-carrier-added Lutetium-177-Edotreotide (n.c.a. 1…
A surgical option which is minimally invasive and available as same-day outpatient procedure1,2,3
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX)– Men in France living with Benign Prostatic Hyperplasia (BPH), a condition in which the pr…
– The REMDACTA clinical trial of Actemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone –
– Genentech will sub…
– The REMDACTA clinical trial of Actemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone –
– Genentech will sub…
Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherap…
Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherap…
Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherap…
Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherap…